Diflucan Side Effects
Generic name: fluconazole
Medically reviewed by Drugs.com. Last updated on Apr 15, 2022.
Note: This document contains side effect information about fluconazole. Some of the dosage forms listed on this page may not apply to the brand name Diflucan.
More frequent side effects include: vomiting. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to fluconazole: oral powder for suspension, oral tablet
Other dosage forms:
Side effects requiring immediate medical attention
Along with its needed effects, fluconazole (the active ingredient contained in Diflucan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fluconazole:
- Chest tightness
- clay-colored stools
- dark urine
- difficulty with swallowing
- fast heartbeat
- hives, itching, or skin rash
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- light-colored stools
- loss of appetite
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- stomach pain, continuing
- unpleasant breath odor
- unusual tiredness or weakness
- upper right abdominal or stomach pain
- vomiting of blood
- yellow eyes and skin
Incidence not known
- Black, tarry stools
- blistering, peeling, or loosening of the skin
- chest pain or discomfort
- decreased urine
- dry mouth
- increased thirst
- irregular or slow heart rate
- joint or muscle pain
- loss of bladder control
- lower back or side pain
- mood changes
- muscle pain or cramps
- muscle spasm or jerking of the arms and legs
- numbness or tingling in the hands, feet, or lips
- painful or difficult urination
- pale skin
- red skin lesions, often with a purple center
- red, irritated eyes
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- sudden loss of consciousness
- swollen glands
- unusual bleeding or bruising
Get emergency help immediately if any of the following symptoms of overdose occur while taking fluconazole:
Symptoms of overdose
- Fearfulness, suspiciousness, or other mental changes
- seeing, hearing, or feeling things that are not there
Side effects not requiring immediate medical attention
Some side effects of fluconazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- change in taste or bad, unusual, or unpleasant (after) taste
- stomach discomfort or upset
Incidence not known
- Hair loss or thinning of the hair
For Healthcare Professionals
Applies to fluconazole: intravenous solution, oral powder for reconstitution, oral tablet
This drug was generally well tolerated. Changes in renal and hematological function test results and hepatic abnormalities reported during therapy with this and comparative agents in some patients, primarily those with serious underlying diseases (e.g., AIDS, cancer); clinical significance and relationship to therapy unclear.
During clinical trials of single-dose therapy, side effects possibly related to therapy were reported in 26% of patients using this drug and 16% of patients using active comparative agents. The most common side effects reported in patients receiving a single 150 mg dose of this drug for vaginitis were headache, nausea, and abdominal pain. Most side effects were of mild to moderate severity.
During clinical trials of multiple-dose therapy, side effects were reported in 16% of patients. Therapy discontinuation occurred in 1.5% and 1.3% of patients due to adverse clinical events and laboratory test abnormalities, respectively. Clinical side effects were reported more often in HIV-infected patients than in non-HIV-infected patients (21% versus 13%), but the patterns in both groups were similar.[Ref]
Rare cases of seizures have been reported, but a causal relationship was difficult to establish, since some of these patients had cryptococcal meningitis or severe underlying disease. Nonetheless, at least 1 case of seizure following a 100 mg oral dose has been reported.
Very common (10% or more): Headache (up to 13%)
Uncommon (0.1% to 1%): Seizures, dizziness, paresthesia, somnolence, vertigo, visual field defect, taste perversion, hyperkinesia, hypertonia
Rare (less than 0.1%): Tremor
Frequency not reported: Dysesthesias[Ref]
Very common (10% or more): Nausea, abdominal pain, diarrhea, vomiting
Common (1% to 10%): Dyspepsia
Frequency not reported: General abdominal discomfort[Ref]
Very common (10% or more): Increased ALT, increased AST
Uncommon (0.1% to 1%): Serum transaminase elevations, cholestasis, jaundice, increased bilirubin
Rare (less than 0.1%): Serious hepatic reactions, hepatic toxicity (including fatalities), hepatic failure, hepatocellular necrosis, hepatitis, hepatocellular damage
Frequency not reported: Hepatic reactions (ranging from mild transient transaminase elevations to clinical hepatitis, fulminant hepatic failure [including fatalities]), transient hepatic reactions (including hepatitis, jaundice), elevated liver function tests (transient and asymptomatic), cholestatic jaundice, fatal hepatic necrosis, increased plasma levels of hepatic enzymes[Ref]
Fatal hepatic reactions have occurred primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications. One reported patient with AIDS experienced acute hepatic necrosis and hepatic failure about 3 weeks after starting this drug.
Transient hepatic reactions have been reported in patients with no other identifiable risk factors. Liver function returned to baseline after stopping this drug.
Serum transaminase elevations (greater than 8 times the upper limit of normal [8 x ULN]; about 1%) and statistically significant increases in AST have been reported. Serum transaminase elevations have been reported primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications, including agents known to be hepatotoxic.
Transaminase elevations greater than 2 to 3 x ULN have also been reported.
Cholestasis, hepatocellular damage, and hepatocellular necrosis have also been reported during postmarketing experience.[Ref]
Very common (10% or more): Rash
Common (1% to 10%): Maculopapular erythema
Rare (less than 0.1%): Angioedema, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), alopecia, acute generalized exanthematous pustulosis, exfoliative dermatitis
Frequency not reported: Reversible alopecia, exfoliative skin disorders (including fatalities)[Ref]
Reversible alopecia has been associated with long-term (2 months or longer) therapy.
In patients with serious underlying diseases (primarily AIDS and malignancy), exfoliative skin disorders have resulted in a fatal outcome.
Acute generalized exanthematous pustulosis, drug eruption, increased sweating, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), and alopecia have also been reported during postmarketing experience.[Ref]
Very common (10% or more): Increased blood alkaline phosphatase
Uncommon (0.1% to 1%): Hypokalemia, anorexia, decreased appetite
Rare (less than 0.1%): Hypercholesterolemia, hypertriglyceridemia[Ref]
Postmarketing reports: Anaphylaxis (including angioedema, face edema, pruritus)[Ref]
Rare cases of exfoliative dermatitis and ulcerative eruptions consistent with Stevens-Johnson syndrome have been reported in association with hypersensitivity reactions.
A 52-year-old female experienced a fixed drug eruption (FDE) when administered a single 400 mg oral dose for extensive pityriasis versicolor. Within 12 hours, she noticed 3 oval, painful, eroded, pigmented patches over her trunk with diameters of 3 to 4 cm and erythematous halos. A clinical diagnosis of FDE due to drug therapy was made. The FDE was confirmed when the patient was rechallenged with a 25 mg oral dose.[Ref]
Rare (less than 0.1%): QT prolongation, torsade de pointes
Most reports of QT interval prolongation and torsades de pointes involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications that may have been contributory.
An 11-year-old male with neurofibromatosis-1 presented to the hospital in septic shock secondary to a perforated gastric volvulus. After initial stabilization, the patient underwent total gastrectomy and multiple peritoneal lavages. Culture of peritoneal fluid showed infection with Candida albicans. Therapy was started with fluconazole 150 mg IV every 12 hours. After starting this drug, the patient developed QT prolongation and complex ventricular arrhythmia. The drug was discontinued. Over the subsequent 36-hours, the patient remained in sinus rhythm except for one brief run of ventricular bigeminy. An ECG recorded 5 months after admission (and about 4 months after cessation of all QT-prolonging medications) showed sinus rhythm with normal heart rate and corrected QT interval.
QT prolongation and torsade de pointes have also been reported during postmarketing experience.[Ref]
Uncommon (0.1% to 1%): Anemia
Anemia, eosinophilia, leukopenia, neutropenia, and thrombocytopenia have been reported, often in patients with severe deep fungal infections or underlying disease.
Spontaneous reports of anemia were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of anemia in the elderly. A causal relationship to drug exposure could not be determined.
Anemia, leukopenia, neutropenia, agranulocytosis, and thrombocytopenia have also been reported during postmarketing experience.[Ref]
Fever, asthenia, fatigue, and malaise have also been reported during postmarketing experience.[Ref]
Uncommon (0.1% to 1%): Thirst, fatigue, malaise, pain, rigors, asthenia, fever, flushing, hot flushes
Rare (less than 0.1%): Face edema
Frequency not reported: Infection due to resistant microorganisms[Ref]
Uncommon (0.1% to 1%): Back pain, myalgia
Frequency not reported: Joint pain, finger stiffness[Ref]
Myalgia has also been reported during postmarketing experience.[Ref]
Insomnia has also been reported during postmarketing experience.
Uncommon (0.1% to 1%): Insomnia, nervousness
Uncommon (0.1% to 1%): Polyuria, renal pain, changes in renal function tests
Frequency not reported: Membranous nephropathy
Postmarketing reports: Acute renal failure[Ref]
A 58-year-old female with a history of hypertension and cervical cancer experienced membranous nephropathy coincident with this drug. The patient presented with increasing generalized edema accompanied by nausea and indigestion for 3 weeks. Clinical findings showed the patient had stage I membranous nephropathy. At initial presentation, the patient's medication history included amlodipine, hydrochlorothiazide, metoclopramide, and levosulpiride. She did not admit to taking fluconazole. Five months after the initial presentation, the patient returned with reports of increasing pedal edema. At that point, the patient admitted to taking this drug once a week for tinea pedis. The patient went into complete remission when the drug was stopped.
Spontaneous reports of acute renal failure were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of renal failure in the elderly. A causal relationship to drug exposure could not be determined.[Ref]
Uncommon (0.1% to 1%): Intermenstrual bleeding, dysmenorrhea, leukorrhea, menorrhagia, uterine spasm, vaginal disorders, female sexual dysfunction
Uncommon (0.1% to 1%): Pharyngitis
Frequency not reported: Respiratory disorders[Ref]
Uncommon (0.1% to 1%): Abnormal vision
Frequently asked questions
- Fluconazole - How long does it take to work?
- Fluconazole - can you drink alcohol while using one dose of 150mg one time?
- I took a fluconazole 150 mg tablet Monday afternoon for a yeast infection.
- What is the dose of fluconazole for tinea? Is it is indicated for tinea infections?
- I am having a reaction after taking fluconazole and would like to know if this is normal?
More about Diflucan (fluconazole)
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (138)
- Drug images
- Compare alternatives
- Pricing & coupons
- Generic availability
- En español
- Drug class: azole antifungals
- Drug Information
- Diflucan (Advanced Reading)
- Diflucan IV (Advanced Reading)
- Diflucan Intravenous (Advanced Reading)
- Diflucan (Fluconazole Injection Solution)
Related treatment guides
1. Clissold SP, Grant SM "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990): 877-916
2. "Product Information. Diflucan (fluconazole)." Roerig Division (2001):
3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
4. Cerner Multum, Inc. "Australian Product Information." O 0
5. Watson SA, McKay FF, Phillips RJ "An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice." Br J Clin Pract 44 (1990): 219-22
6. Cloud GA, Saag MS, Powderly WG, et al. "Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis." N Engl J Med 326 (1992): 83-9
7. Joseph JA, Knirsch AK, Robinson PA "Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents." Rev Infect Dis 12 (1990): s349-63
8. Inman W, Pearce G, Wilton L "Safety of fluconazole in the treatment of vaginal candidiasis - a prescription-event monitoring study, with special reference to the outcome of pregnancy." Eur J Clin Pharmacol 46 (1994): 115-8
9. Gupta AK, Ryder JE "The use of oral antifungal agents to treat onychomycosis." Dermatol Clin 21 (2003): 469-79, vi
10. Cadena J, Thompson GR 3rd, Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v
11. Ikemoto H "A clinical study of fluconazole for the treatment of deep mycoses." Diagn Microbiol Infect Dis 12 (1989): s239-47
12. De Wit S, Clumeck N "Fluconazole in the treatment of fungal infections associated with AIDS." Infection 17 (1989): 121-3
13. Lafaix C, Vincent-Ballereau FN, Patey ON "Fluconazole: review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections." Pharm Weekbl Sci 13 (1990): 45-57
14. Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991): 585-6
15. Bozzette SA, Chiu J, Larsen RA, et al. "A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome." N Engl J Med 324 (1991): 580-4
16. Morrow JD "Fluconazole: a new triazole antifungal agent." Am J Med Sci 302 (1991): 129-32
17. Winston DJ, Greenfield RA, Goodman JL, et al. "A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation." N Engl J Med 326 (1992): 845-51
18. Elias E, Franklin IM, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990): 565
19. Berenguer J, Munoz P, Moreno S, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991): 1020-1
20. Cal SX, Nightingale SD, Peterson DM, et al. "Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients." AIDS 6 (1992): 191-4
21. Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992): 111-2
22. Ferrell LD, Hanks DK, Jacobson MA "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994): 188-90
23. Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994): 1177-81
24. Guillaume MP, Cogan E, Deprez C "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996): 165-8
25. Bamberger DM, Johnson PC, Mckinsey DS, Pappas PG, Kauffman CA, Perfect J, Sharkey PK, Chapman SW, Hamill R, Sobel JD "Alopecia associated with fluconazole therapy." Ann Intern Med 123 (1995): 354-7
26. Goldsmith LA "Alopecia associated with fluconazole therapy." Ann Intern Med 125 (1996): 153
27. Shear NH "Alopecia associated with fluconazole therapy." Ann Intern Med 125 (1996): 153
28. Peralta F, Boggavarapu J, Craig TJ "Desensitization for fluconazole hypersensitivity." J Allergy Clin Immunol 98 (1996): 845-6
29. Abbott M, Hughes DL, Kinghorn GR, Patel R "Angio-oedema after fluconazole." Lancet 338 (1991): 633
30. Gussenhoven MJ, Peereboom-Wynia JD, Haak A, van Wout JW "Stevens-Johnson syndrome after fluconazole." Lancet 338 (1991): 120
31. Neuhaus G, Pavic N, Pletscher M "Anaphylactic reaction after oral fluconazole." Br Med J 302 (1991): 1341
32. Thami GP, Gupta R "Fixed drug eruption caused by itraconazole: Reactivity and cross reactivity." J Am Acad Dermatol 58 (2008): 521-522
33. Beecker J, Colantonio S "Fixed drug eruption due to fluconazole." CMAJ 184 (2012): 675
34. Esch JJ, Kantoch MJ "Torsades de pointes ventricular tachycardia in a pediatric patient treated with fluconazole." Pediatr Cardiol 29 (2007): 210-3
35. Grayson ML, McMahon JH "Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis." Am J Health Syst Pharm 65 (2008): 619-23
36. Agarwal A, Chugh KS, Sakhuja V "Fluconazole-induced thrombocytopenia." Ann Intern Med 113 (1990): 899
37. Mercurio MG, Elewski BE "Thrombocytopenia caused by fluconazole therapy." J Am Acad Dermatol 32 (1995): 525-6
38. Pappas PG, Kauffman CA, Sobel JD "Alopecia associated with fluconazole therapy." Ann Intern Med 125 (1996): 153-4
39. Kalivas J "Thrombocytopenia caused by fluconazole." J Am Acad Dermatol 35 (1996): 284
40. Mercurio MG, Elewski BE "Thrombocytopenia caused by fluconazole - reply." J Am Acad Dermatol 35 (1996): 284
41. Kim H, Park J, Shin GT, Yim H "Membranous nephropathy associated with fluconazole treatment." Am J Kidney Dis 49 (2007): 318-22
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.